Circulating Gene Expression Assay as a Diagnostic and Prognostic Biomarker for Pancreatic Neuroendocrine Tumors in MEN1
Authors' conclusion
In line with previous studies in non-MEN1 associated NET, in MEN1, a circulating NET gene expression assay identified patients without any manifestations from PanNETs. The mNET assay did not predict PanNET development, progression, or metastasis. The underlying genetic condition, epigenetic modifications, microadenomas, and coexistence of multiple manifestations may impact circulating RNA profiles. Further research should explore alternative biomarkers or develop clinico-molecular algorithms for personalized management strategies in MEN1.
Study context
- Population
- MEN1 patients enrolled July 2016–June 2017; blood in PAXgene tubes, NETest recalibrated for MEN1 pancreatic neuroendocrine tumors (PanNETs) (mNET), performed at baseline
- Participants
- 110 eligible patients
- Outcome
- mNET assay diagnostic and predictive value (AUC)
- Follow-up
- 39 months (range 12-48 months)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
follow-up 39 months (range 12-48 months)
- Baseline: mNET differentiated patients without manifestations from patients with only PanNETs
- P = .04
- AUC for predicting PanNET development
- 0.65 (P = .15)
- AUC for PanNET growth (not predicted)
- 0.49
- AUC for number of PanNETs (not predicted)
- 0.54
- AUC for new metastatic disease (not predicted)
- 0.39
- AUC for metastasis progression (not predicted)
- 0.46
- PanNETs at baseline
- 60%
- Developed PanNETs during follow-up
- 9%
Observational data: associations, not effects.
Original publication
Circulating Gene Expression Assay as a Diagnostic and Prognostic Biomarker for Pancreatic Neuroendocrine Tumors in MEN1. J Clin Endocrinol Metab. Published 24 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →